mesenchymal stem cell therapy (DWP710) / Daewoong Pharma - LARVOL DELTA

PT. Daewoong Infion from Korea Receives Government Permit to Conduct Clinical Trials for COVID-19 Treatment [Google translation] (Industry Coid) - "Daewoong Pharmaceutical Korea and PT. Daewoong Infion...has signed an MoU on Clinical Trial of COVID-19 treatment with the Indonesian Ministry of Health...Based on the MOU, PT. Daewoong Infion will conduct a clinical trial of casmostat and niclosamide on COVID-19 patients in Indonesia....Daewoong Pharmaceutical Korea is currently undergoing phase I clinical trials of niclosamide in Korea, Australia and India, and plans to announce the results of its Phase II clinical trials conducted in various countries in the first half of 2021....Last year, PT. Daewoong Infion has signed an MoU with the Ministry of Health of the Republic of Indonesia to conduct a clinical trial of stem cell-based COVID-19 treatment (DWP710)...The company is preparing to apply for a license to carry out phase II clinical trials in Korea after completing phase I clinical trials in Indonesia."

Cytokine storm • New P2 trial • P2 data • Infectious Disease • Novel Coronavirus Disease

Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients (clinicaltrials.gov) - P1; N=9; Completed; Sponsor: Ina-Respond; Active, not recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • IL6

Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients (clinicaltrials.gov) - P1; N=9; Active, not recruiting; Sponsor: Ina-Respond; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients (clinicaltrials.gov) - P1; N=9; Recruiting; Sponsor: Ina-Respond; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

Daewoong to conduct P1 trial of Covid-19 treatment in Indonesia (Korea Biomedical Review) - "Daewoong Pharmaceutical said that the Indonesian health regulators have approved phase 1 clinical trial of its DWP710, a Covid-19 treatment using mesenchymal stem cells....With the approval, Daewoong plans to conduct the clinical trial in Indonesia, along with its local joint venture Daewoong Infion....Based on the results of the Indonesian phase 1 clinical trial, the company plans to conduct further phase 2 clinical trial of the drug in Korea."

New P1 trial • Non-US regulatory • Infectious Disease • Novel Coronavirus Disease